Work

Use of a PD-1 checkpoint inhibitor in a patient with ultra-high-risk gestational trophoblastic neoplasia and gastrointestinal metastases

Year: 2024

Type: article

Abstract: • GTN are rare diseases that are typically chemotherapy-responsive. • Gastrointestinal metastases from GTN are extremely rare and indicate a poor prognosis. • The use of PD-1/PD-L1 checkpoint inhibitors in low-risk GTN is not well-established. • This case supports continued investigation of PD-1/PD-L1 inhibitor use as a part of first-line treatment for high risk GTN. Gestational trophoblastic neoplasia (GTN) are rare diseases that are typically chemo-responsive. While the majority of patients are cured with chemotherapy alone, a small portion of cases are fatal due to chemotherapy resistance. Risk factors for treatment failure are liver and brain metastases, extensive disease, and chemo-refractory disease. Gastrointestinal (GI) metastases are extremely rare and indicate a poor prognosis. Treatment with immunotherapy has been studied and included in treatment guidelines for high-risk and chemotherapy-resistant GTN. This case reports on the early use of programmed cell death protein 1 (PD-1) inhibitor in combination with systemic chemotherapy in a patient with ultra-high risk GTN with GI metastases.

Source: Gynecologic Oncology Reports

DOI: 10.1016/j.gore.2024.101530

Authors: Amalia Brawley, Casey Moffitt, Shaina Feldman Bruce, Caitlin Stashwick Farabaugh, Edward Podczaski, Joel Sorosky

Institutions: Pennsylvania State University, Penn State Milton S. Hershey Medical Center

Language: English

Topic: Gestational Trophoblastic Disease Studies

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $750